28 related articles for article (PubMed ID: 3400992)
1. [Effects of sotalol on blocked suprahepatic pressure in cirrhotic patients].
Deflandre J; Gillard V; Pirotte J; el Allaf D; Carlier J
Ann Gastroenterol Hepatol (Paris); 1987 Dec; 23(7):359-61. PubMed ID: 3435033
[TBL] [Abstract][Full Text] [Related]
2. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
Bosch J; Kravetz D; Rodes J
Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897
[TBL] [Abstract][Full Text] [Related]
3. [The effect of sotalol on cirrhotic portal hypertension. Results of a preliminary study of cardiac and hepatic hemodynamics].
Deflandre J; Pirotte J; el Allaf D; Carlier J
Biomed Pharmacother; 1986; 40(4):154-7. PubMed ID: 3790709
[TBL] [Abstract][Full Text] [Related]
4. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Schneider AW; Kalk JF; Klein CP
Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
[TBL] [Abstract][Full Text] [Related]
5. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Deibert P; Schumacher YO; Ruecker G; Opitz OG; Blum HE; Rössle M; Kreisel W
Aliment Pharmacol Ther; 2006 Jan; 23(1):121-8. PubMed ID: 16393289
[TBL] [Abstract][Full Text] [Related]
6. [Effect of a serotonin S2 receptor antagonist on portal hypertension due to cirrhosis. Preliminary results of a heart and liver hemodynamic study].
Deflandre J; Pirotte J; Etienne M; Carlier J
Ann Gastroenterol Hepatol (Paris); 1988; 24(3):103-5. PubMed ID: 3400992
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients.
Thalheimer U; Leandro G; Samonakis DN; Triantos CK; Patch D; Burroughs AK
Dig Liver Dis; 2005 Aug; 37(8):601-8. PubMed ID: 15908290
[TBL] [Abstract][Full Text] [Related]
8. [Pulmonary hypertension complicating portal hypertension: portopulmonary hypertension].
Katsuta Y; Zhang XJ; Aramaki T
Nihon Rinsho; 2001 Jun; 59(6):1186-92. PubMed ID: 11411134
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of action and use of antagonists of serotonin receptors S2, especially ketanserin, in the treatment of various diseases of the cardiovascular system].
Wiecek A; Grzeszczak W
Pol Tyg Lek; 1987 Mar; 42(10):304-8. PubMed ID: 3299308
[No Abstract] [Full Text] [Related]
10. Hemodynamic effects of the anti-hypertensive agent ketanserin in hypertension in man.
Weiss YA; Fournier V; Pannier B; Laurent S; Safar ME
Acta Cardiol; 1987; 42(5):329-37. PubMed ID: 3321806
[TBL] [Abstract][Full Text] [Related]
11. Portal hypertension: serotonin and pathogenesis.
Lebrec D
Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():33-5. PubMed ID: 2285648
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
